Evidence map›Paper›PMID 40480146›Full record

ArticleTranslational oncology2025

Development and validation of nomogram including mutations in angiogenesis-related genes as risk factors for HCC patients treated with TACE.

Wanqing Shen, Zhi Li, Jinyi Huang, Guixiong Zhang, Yiyang Tang, Wenzhe Fan, Jiaping Li

Abstract read
In one paragraph

Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wanqing ShenDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Zhi LiSchool of Public Health, Guangzhou Medical University, Guangzhou, 511436, China.
Jinyi HuangSchool of Public Health, Guangzhou Medical University, Guangzhou, 511436, China.
Guixiong ZhangDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Yiyang TangDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Wenzhe FanDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Jiaping LiDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. Electronic address: lijiap@mail.sysu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs a vascular-rich solid tumor, hepatocellular carcinoma (HCC) patients with poor transarterial chemoembolization (TACE) respone or treatment failure may correlate with tumor angiogenesis in residual disease. However, their relationship remains unclear. This study aims to explore the relationship between angiogenesis-related genes and TACE failure in patients with HCC and to develop a predictive model for assessing treatment outcomes. MATERIALS AND

methodsSomatic mutation profiles of 165 patients with HCC treated with TACE were analyzed using whole-exome sequencing (WES). Multivariate Cox regression analysis was performed to calculate the genetic risk score (GRS) for angiogenesis-related gene mutations. The participants were randomly divided into training and validation groups. In the training set, independent prognostic factors of TACE-treated patients with HCC were screened using univariate Cox-LASSO-stepwise Cox regression, and a nomogram was established and evaluated using the receiver operating characteristic curve, calibration curve, and decision curve analysis of the two sets.

resultsAmong 165 patients, significant genetic alterations were identified, with TP53 being the most frequently mutated gene. Mutations in FGFR4, MST1R, and RECK were associated with the treatment efficacy of patients receiving TACE treatment, and the constructed GRS was associated with poor prognosis. Furthermore, AFP, ALT, AST, PLR, PD-L1 immune drug treatment, and GRS were confirmed as independent factors affecting the prognosis of patients with HCC treated with TACE. A nomogram was constructed, which demonstrated excellent discrimination, calibration, and clinical benefits in both the training and validation sets.

conclusionThese findings highlight the critical role of angiogenesis-related genes in predicting TACE outcomes in patients with HCC and indicate that the developed prognostic model and nomogram can serve as valuable tools to predict prognosis based on the GRS of angiogenesis-associated gene mutations. IMPLICATIONS FOR PRACTICE: Our findings highlight the critical role of angiogenesis-related genes in predicting TACE outcomes in HCC patients. The developed prognostic model and nomogram can serve as valuable tools for clinicians, enhancing decision-making and treatment strategies for HCC management.

Indexed as

AngiogenesisGenetic risk scoresHepatocellular carcinomaTransarterial chemoembolizationWhole-exome sequencing

Identifiers

PMID40480146
PMCPMC12169781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.